1996 Fiscal Year Final Research Report Summary
DEVELOPMENT OF BIOARTIFICIAL ENDOCRINE PANCREAS USING GLUCOSE-RESPONSIVE B-CELL LINE MIN6
| Project/Area Number |
07558247
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 試験 |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | Osaka University (1996)
Tohoku University (1995) |
|---|
Principal Investigator |
MIYAZAKI Jun-ichi Osaka University Medical School, Professor, 医学部, 教授 (10200156)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKEDA Hiroaki Fuji Systems Inc., Research Institute, Investigator, 研究所, 研究員
OHGAWARA Hisako Tokyo Women's Medical College, Medical Research Institute, lecturer, 総合研究所, 講師 (10075468)
AKAIKE Toshihiro Tokyo Institute of Technology, Faculty of Bioscience and Biotechnology, Professo, 生命理工学部, 教授 (30101207)
|
|---|
| Project Period (FY) |
1995 – 1996
|
| Keywords | diabetes / bioartificial endocrine pancreas / glucose transporter / MIN6 cell / insulin secretion / グルコーストランスポーター |
|---|
| Research Abstract |
Embedded culture of pancreatic b-cells derived from a transgenic insulinoma (MIN6 cells) was studied in vitro and in vivo. The MIN6 cells were enmeshed in an agarose-PVMA-collagen matrix for long-term maintenance. The cells formed islet-like cell clusters (ICCs) in the mixed matrix. MIN6 cells exhibited normal b-cell function for up to 35 days in the matrix, and the cells were much better preserved with nicotinamide than without it. MIN6 cells were suspended in the matrix and transferred into diffusion chambers to create a bio-artificial endocrine pancreas (Bio-AEP). In streptozotocine-induced diabetic rats with implanted Bio-AEP but without any immunosuppressants, a return to normoglycemia was observed for up to 50 weeks after transplantation. Our results indicate that Bio-AEP containing MIN6 cells should be useful for the study of xenotransplantation and the development of a bioartificial endocrine pancreas, and opens a new field in the therapy of insulin-dependent diabetes mellitus.
|
